Guardant Health Inc. (GH) and Hikma Pharmaceuticals have entered into an agreement to collaborate on the promotion of Guardant Health's range of liquid and tissue biopsy tests. The focus will be on cancer screening, recurrence monitoring, and tumor mutation profiling, covering all solid cancers in countries throughout the Middle East and North Africa.
The tests offered include Shield for cancer screening and early detection, Guardant Reveal for minimal residual disease detection and recurrence monitoring, and Guardant360 and Guardant360 Tissue Next for comprehensive genomic profiling across all solid cancers.
The number of cancer cases in the Middle East and North Africa is projected to double by the year 2040.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.